TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

Blood

Volumn 105, Issue 9, 2005, Pages 3413-3419

  Secchiero, Paola ^a   Corallini, Federica ^b   Di Iasio, Maria Grazia ^b   Gonelli, Arianna ^b   Barbarotto, Elisa ^b   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CCL8 CHEMOKINE; CHEMOKINE; CYTOKINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; EXPOSURE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; STEADY STATE;

EID: 18244373214     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-4111     Document Type: Article

References (33)

1. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol. 2004;4:432-444.
2. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-3561.
3. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood. 2002;100:3853-3860.
4. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001;2:123-128.
5. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol. 2001;13:569-577.
6. Eriksson EE. Leukocyte recruitment to atherosclerotic lesions, a complex web of dynamic cellular and molecular interactions. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:309-325.
7. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(suppl 1):1127-1133.
8. Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation. 2003;108:472-478.
9. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
10. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
11. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66-75.
12. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000;482:193-199.
13. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107:2250-2256.
14. Zauli G, Pandolfi A, Gonelli A, et al.TNF-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003;92:732-740.
15. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol. 2003;171:1526-1533.
16. Saeed RW, Varma S, Peng T, Tracey KJ, Sherry B, Metz CN. Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J immunol. 2004;173:6376-6383.
17. SuperArray Bioscience Corporation. Gene List. http://www.superarray.com/ gene_array_product/HTML/HS-602.3.html. Accessed May 2, 2004.
18. SuperArray Bioscience Corporation. GEArray Service. http://www. superarray.com/microarrays.php. Accessed May 2, 2004.
19. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J. Synergy between proinflammatory ligands of G protein coupled receptors in neutrophil activation and migration. J Leuk Biol. 2004;76:185-194.
20. Srinivasan S, Bolick DT, Hatley ME, et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem. 2004;279:31930-31936.
21. Griffioen AW, Damen CA, Blijham GH, et al. Tumor angiogenesis is accompanied by a decreased inflammatory response to tumor-associated endothelium. Blood. 1996;88:667-673.
22. Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 2004;101:5634-5639.
23. Pritzker M, Scatena M, Glachelli CM. The role of osteoprotegerin and TRAIL in human microvascularendothelial cell survival. Mol Biol Cell. 2004;15:2834-2841.
24. Hillyer P, Mordelet E, Flynn G, Male D. Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leukocyte migration. Clin Exp Immunol. 2003;134:431-441.
25. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004;36:98-118.
26. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416-421.
27. Kunkel EJ, Butcher E. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1-4.
28. Wajant H. TRAIL and NfkappaB signaling-a complex relationship. Vitam Horm. 2004;67:101-132.
29. Bertolotto C, Ricci JE, Luciano F, Mari B, Chambard JC, Auberger P. Cleavage of the serum response factor during death receptor-induced apoptosis results in an inhibition of the c-Fos promoter transcriptional activity. J Biol Chem. 2000;275:12941-12947.
30. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC Chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004;25:201-208.
31. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LW. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149:39-42.
32. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
33. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194.